BOLT News and Press, Bolt Biotherapeutics Inc. From 11/12/21

Presentation of preclinical data supporting the selection of BDC-2034, an ISAC targeting CEA, as Bolt Biotherapeutics’ second Boltbody™ ISAC development candidate Demonstration of the novel, multifunctional mechanism for an ISAC which combines PD-1/PD-L1 axis inhibition ...

Bolt Biotherapeutics (NASDAQ:BOLT): Q3 GAAP EPS of -$0.63 beats by $0.02. Revenue of $0.8M beats by $0.3M. Press Release Cash, cash equivalents, and marketable securities were $290.5M as of September 30, 2021, compared to $310.9M as of June 30, 2021. Bolt Biotherapeutics expects this cas...

–BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021 –Strong cash position of $295.5 million expected to fund operations through the end of 2023 REDWOOD CITY, C...

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syste...

SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy...

REDWOOD CITY, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune...

Today, we take our first look at Bolt Biotherapeutics, a small developmental firm focused on cancer immunotherapeutics and myeloid biology. The company just came public earlier this year but already is deep in 'Busted IPO' territory. A full investment analysis follows in the parag...

Several people in the U.K. are vocal about their experience with taxi apps such as Uber Inc. ( NYSE: UBER ) and Bolt Biotherapeutics ( NASDAQ: BOLT ). A section of users told CNBC that the apps did not connect them to a chauffeur. As a result, they were late for a meeting or lef...

REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immun...

REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syst...